Compare DCBO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | ADCT |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.9M | 484.4M |
| IPO Year | 2020 | 2019 |
| Metric | DCBO | ADCT |
|---|---|---|
| Price | $18.39 | $4.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $32.00 | $7.50 |
| AVG Volume (30 Days) | 278.2K | ★ 801.2K |
| Earning Date | 01-01-0001 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,837,000.00 |
| Revenue This Year | $12.54 | $14.96 |
| Revenue Next Year | $11.82 | $1.06 |
| P/E Ratio | $22.04 | ★ N/A |
| Revenue Growth | N/A | ★ 1.84 |
| 52 Week Low | $16.07 | $1.05 |
| 52 Week High | $33.69 | $4.80 |
| Indicator | DCBO | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 50.45 | 64.33 |
| Support Level | $18.11 | $3.25 |
| Resistance Level | $20.15 | $4.71 |
| Average True Range (ATR) | 0.81 | 0.24 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 71.88 | 84.56 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).